NASAL DRUG DELIVERY MODE MARKET ANALYSIS

Drug delivery refers to the technology utilized to present the drug to the desired body site for drug release and absorption. Nasal drug administration has been used as an alternative route for the systemic availability of drugs restricted to intravenous administration. It is the most preferred route of administration for the treatment of allergic and non-allergic rhinitis, acute treatment of migraine, pain, and nasal congestion associated with rhinitis, common cold, or sinusitis. Nasal route has shown remarkable advantages that include rapid and high systemic availability, possibility of targeting drugs directly from the nasal cavity to brain, and avoidance of first pass metabolism by the liver. Intranasal drug delivery (or nasal drug delivery) offers a rapid onset of therapeutic effects (local or systemic).

Market Statistics:

The global nasal drug delivery mode market was valued at US$ 48,200.0 Mn in 2020 and is forecast to reach a value of US$ 75,766.8 Mn by 2028 at a CAGR of 5.8% between 2021 and 2028.

North America held dominant position in the global nasal drug delivery mode market in 2020, accounting for 33.3% share in terms of volume, followed by Europe and Asia Pacific, respectively.

Figure 1. Global Nasal Drug Delivery Mode Market Share (%), by Region, 2020

To learn more about this report, request sample copy

Recent Developments:

1. In June 2020, GlaxoSmithKline (GSK) added a natural saline nasal spray for the relief of hay fever and other allergy symptoms to its Piri range. The PiriNatural spray can help reduce nasal congestion caused by allergies by cleaning and washing nasal cavities with isotonic seawater and aloe vera, according to the company.
2. In March 2020, Evolve BioSystems, Inc. announced a collaboration with Janssen Research & Development to conduct a clinical study in children at risk for developing atopic dermatitis. It aims to investigate whether infant probiotic evivo can reduce development of early childhood atopic dermatitis, which is implicated in asthma, allergic rhinitis, and food allergies.

Market Drivers:

1. Increasing patient preference for nasal drug delivery (due to easy administration and better efficacy) is expected to boost the growth of the global nasal drug delivery mode market during the forecast period. For instance, in April 2022, Upperton Pharma Solutions launched the nasal delivery development platform, named UpperNose, to make it easier for innovators to access the capabilities necessary for the development of nasal dosage formulations.
2. Growing incidence of respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and asthma, is expected to augment the growth of the global nasal drug delivery mode market during the forecast period. For instance, according to the World Health Organization (WHO), COPD was the third leading cause of death worldwide, causing 3.23 million deaths, and asthma affected an estimated 262 million people and caused 455,000 deaths in 2019.

Figure 2. Global Nasal Drug Delivery Mode Market Share (%) in Terms of Value, by Therapeutic Application, 2021

To learn more about this report, request sample copy

Market Restraints:

1. Complications associated with the overuse of nasal sprays are expected to hamper the growth of the global nasal drug delivery mode market. Nasal sprays may ease nasal congestion, but overusing them can backfire into a condition called rhinitis medicamentosa. Overuse of nasal sprays can also lead to other side effects, such as coughing, headache, increased risk of sinus infection, nasal passage swelling (inflammation), and, rarely, tears in the nostril membranes.
2. Stringent rules and regulations or regulatory hurdles are also expected to hinder growth of the global nasal drug delivery mode market. Nasal drug delivery can be assessed by a variety of means and regulatory agencies. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have published a set of guidelines and regulations proposing in vitro test methods for the characterization of nasal drug products.

Market Opportunities:

1. Increase in demand for home healthcare devices and growing adoption of self-administration practices is expected to provide lucrative growth opportunities for players in the global nasal drug delivery mode market. For instance, in April 2022, Catalent announced the expansion of its nasal capabilities at its Morrisville, Research Triangle Park (RTP) facility to provide world-class services for the development and manufacturing of unit and bi-dose nasal spray products.
2. Increasing prevalence of chronic diseases, such as chronic rhinosinusitis, is expected to offer significant growth opportunities for players in the global nasal drug delivery mode market. For instance, in June 2019, Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has approved Dupixent (dupilumab) for use with other medicines to treat chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease is not controlled.

Market Trends/Key Takeaways:

1. Outbreak of COVID-19 (pandemic) is expected to propel the growth of the global nasal drug delivery mode market. For instance, in August 2021, Glenmark Pharmaceuticals and SaNOtize Research & Development Corp. teamed up to manufacture, market, and distribute its Nitric Oxide Nasal Spray (NONS) for the treatment of COVID-19 in India and other Asian markets including Hong Kong, Malaysia, Singapore, and other countries.
2. Introduction of novel products and/or frequent approvals and launches of novel products are expected to aid in the growth of the global nasal drug delivery mode market. For instance, in March 2019, Aptar Pharma announced that its Bidose nasal spray device was recently approved by the U.S. FDA for a breakthrough therapy in the field of depression.

Competitive Landscape:

1. Merck & Co., Inc.
2. GlaxoSmithKline Plc
3. Astra Zeneca
4. Johnson & Johnson Services Inc.
5. Mystic Pharmaceuticals
6. Bausch Health
7. PendoPharm Inc.
8. Optinose
9. Cadila Pharmaceutical s Ltd.
10. 3M
11. Dr. Reddy Laboratories
12. Aptar Group Inc.
13. Neurelis Inc.
14. ENT Technologies Pty Ltd.
15. Becton, Dickinson and Company